Abstract: OCT4, a member of the POU family of gene products, is an octamer motif-binding transcription factor. As it is known to play a crucial role in cancer processes including proliferation, invasion, and chemoradioresistance, it is important to identify the direct targets of OCT4 in living cancer cells. Here, chromatin immunoprecipitation-sequencing (ChIP-seq) was used to identify OCT4 binding sites in glioblastoma cancer cells. The results showed that 5438 OCT4 binding sites were localized in the glioblastoma cancer genome and that these sites contained a consensus sequence TTTkswTw (k=T or G, s=C or G, w=A or T), which occurred 3931 times in 2312 OCT4 binding regions. Furthermore, binding motifs of some other transcription factors were identified in OCT4 binding regions. Our results provide a valuable dataset for understanding gene regulation mechanisms underlying the function of OCT4 in glioblastoma cancer.
Introduction
OCT4, a member of the POU family of gene products (Verrijzer et al., 1992; Dekker et al., 1993; Herr and Cleary, 1995) , is an octamer motif-binding transcription factor (TF), which is highly expressed in stem cells (Schoorlemmer et al., 1995; Pesce et al., 1998) . OCT4 has been considered as a key molecule which could induce somatic cell pluripotency (Takahashi and Yamanaka, 2006; Takahashi et al., 2007) . OCT4 is also essential for maintaining undifferentiated and pluripotent populations of cells (Yu et al., 2007) . Kim et al. (2009a; 2009b) reported that OCT4 can directly reprogram adult mouse and human neural stem cells to induced pluripotent stem (iPS) cells. These studied showed that OCT4 plays an important role in conferring the stemness of cells.
In general, cancer cells are similar to early embryonic cells with the properties of immortality, undifferentiation, and invasion (Monk and Holding, 2001) . So, it is vital to study genes associated with embryogenesis and tumorigenesis. In recent years, there have been some reports on the deregulated expression of OCT4 in several cancers, such as human embryonal carcinomas (Kraft et al., 1996) , testicular germ cell tumors and seminomas (Cheng et al., 2007) , lung cancer (Chen et al., 2008) , and bladder carcinomas (Atlasi et al., 2007) . It is possible that aberrant expression of OCT4 may contribute to the progression of these cancers. Atlasi et al. (2007) found that OCT4 is overexpressed in bladder cancer tissues compared with normal bladder tissues and can enhance bladder cancer cell migration and invasion. Schreiber et al. (1994) showed that the expression of OCT4 was significantly higher in high-grade primary gliomas than in low-grade gliomas at the mRNA and protein levels (Schreiber et al., 1994) . Chen et al. (2008) demonstrated that the expression of OCT4 is crucial in maintaining the self-renewing, cancer stem-like, and chemoradioresistance properties of CD133 + lung cancer cells. So far, system-wide investigation of the function of OCT4 has been focused only on embryonic cells. To understand the function of OCT4 in a genomewide manner in cancer, we have used chromatin immunoprecipitation-sequencing (ChIP-seq) to determine the genome binding sites of OCT4 in living glioblastoma cells. We report here the genome-wide targets of OCT4 in glioblastoma cells identified by ChIP-seq, which provide us with a comprehensive dataset for improving our understanding of the role of OCT4 in tumor development.
Materials and methods

Cell culture
U251 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS).
Immunoblot analysis
Cells were lysed in RIPA cell lysis buffer (25 mmol/L Tris-HCl (pH 7.6), 150 mmol/L NaCl, 0.01 g/ml NP-40, 0.01 g/ml sodium deoxycholate, 1 g/L sodium dodecyl sulfate (SDS)) containing protease inhibitor cocktail kit (Pierce, Rockford, IL, USA). A total of 20 µg of protein was loaded for Western blot analysis. The OCT4 (ab18976) antibody was purchased from Abcam (Cambridge, MA, USA).
ChIP-seq procedure
The aforementioned anti-OCT4 antibody and normal IgG (SC-2027; Santa Cruz, CA, USA) were used for immunoprecipitation. Cells (1×10 7 U251) were fixed with 1% fresh formaldehyde and lysed in lysis buffer according to the protocol of Fang et al. (2010) . The nuclei were resuspended and sonicated on ice to chromatin of 200-500 bp DNA. A total of 50 µl of Dynal protein G beads, 5 µg of antibody, and the sonicated chromatin were incubated at 4 °C overnight. The precipitated immunocomplex was treated with proteinase K at 65 °C for 2 h and DNA was purified with QIAquick polymerase chain reaction (PCR) purification kit (Qiagen, USA). ChIP DNA was amplified, ligated with adaptor, and repaired at the DNA end. The 150 bp DNA fragments were isolated from agar gel and sequenced with a Solexa Illumina 2G genetic analyzer.
ChIP-seq analysis
Solexa pipeline analysis was performed as described by Lin et al. (2009) and Fang et al. (2010) . The SOAP program was used to map the 36 nucleotide sequence tags to the human genome with two mismatches allowed Fang et al., 2011) . We used the MACS program to identify the enriched peaks of the OCT4 binding sites with an IgG ChIP group dataset as control. The program parameters were set as follows: P-value cutoff of 1.00×10 −5 , model fold of 32, tag size of 36 bp of 5′ sequences, and effective size of 2.70×10 9 for the human genome. We annotated the datasets with the HG19 database using the CisGenome program (Ji et al., 2008) .
Validation of ChIP-seq targets by real-time PCR
A list of binding peaks was selected and quantitative real-time PCR was performed to validate the OCT4 binding region dataset. The primers used are listed in Table 1 .
Analysis of distance to transcription start site
We used annotations of the UCSC human genome HG19 database to calculate the distance from transcription start sites (TSSs) to the binding sites. We also considered the strand's direction when we calculated the distance: for the positive strand, the distance was from the TSS start position to the end position of the OCT4 binding region; for the negative strand, the distance was to the OCT4 binding region start position.
Motif scanning and identification
For the identification of the novel motifs, we extended the OCT4 binding sites observed by ChIP-seq to 100 bp 3′ and 5′, then retrieved the sequences in the FASTA format. We used the RepeatMasker program (http://www.repeatmasker.org) to mask all human repeats in these sequences. To find out the up-regulation motifs, a program named MotifSampler (http://bioinformatics.psb.ugent.be/webtools/ plantcare/html/Motif_Sampler.html) was used (default parameters were applied). We used the WebLogo program (http://weblogo.berkeley.edu/) (Crooks et al., 2004) to calculate the consensus sequences.
Gene ontology analysis
To analyze the enriched Gene Ontology (GO) terms of all evidence levels and categories statistically, we used the program High-Throughput GoMiner (Zeeberg et al., 2005) .
Results
Specificity of the antibody
The specificity of the antibody is essential to the success of ChIP-seq experiments. We characterized the anti-OCT4 antibody used in our study using Western blot. The antibody recognized a distinct band of the appropriate size in glioblastoma cells (Fig. 1) .
ChIP-seq analysis of OCT4 binding regions in glioblastoma cells
To observe the genome-wide binding patterns of OCT4, a novel approach for the identification of TF binding sites, ChIP-seq technology, was applied (Barski et al., 2007; Johnson et al., 2007) . From sequence analysis, we mapped a total of 217 688 and 421 892 sequence tags uniquely to the human genome (allowing two mismatches) for IgG and OCT4, respectively. MACS was then applied to analyze the enriched binding regions of OCT4. With a P-value of <0.01, 5 438 OCT4 binding regions were identified in the human genome with IgG ChIP-seq as a negative control (Table S1 ). We randomly picked ten genes and confirmed that all ten gene DNA binding regions were enriched in the OCT4 IP DNA compared to the IgG IP DNA, using real-time PCR (Fig. 2) . This suggested that the false positive rate of our dataset was negligible. With 5 438 binding regions corresponding to 3 798 genes, our results suggested that on average there were 1.4 enriched regions per gene. The OCT4 binding regions were mapped to the human genome (Table S1 ) using database HG19 with a cutoff-value of 50 kb distance. We calculated the distance from the OCT4 binding region to the known genes' TSSs and tabulated the frequency of OCT4 binding sites across the 5-kb distance interval before and after the TSSs. The OCT4 binding sites were around the TSSs, with about 41.05 % of binding sites mapped within a 5-kb distance (Fig. 3) . We analyzed the function of OCT4 binding genes using the GoMiner program with Level 3 of the biology process. The enriched GO terms are shown in 
Identification of DNA binding consensus sequences and OCT4-associated TFs in the OCT4 binding regions
We applied the program MotifSampler to identify the enriched and unique consensus sequences in the binding regions of human OCT4 in glioblastoma cells. A consensus sequence of TTTkswTw (w=A or T, k=T or G, s=C or G) with a very high log likelihood score (17 971.1) was found. The Table S2 shows this consensus sequence's output matrix and Table S3 shows 3 931 instances of this motif in 2 312 OCT4 binding regions. The logo of the consensus sequence is shown in Fig. 4 . The MotifSampler program was used to systematically search for other known potential TFs which bind to the OCT4 binding regions and cooperate to regulate gene expression. All matrices of the TF's motifs were scanned and the matched matrices were tabulated and calculated. Among the top known TF's matrices identified as OCT cooperators, matching in more than 30% of cases, the hepatocyte nuclear factor (HNF) family, the fork head transcription factor (FOX) family, the OCT family, the sex-determining region of Y-chromosome (SRY) family, and several other TFs including CEBP, PIT1_Q6, POU1F1_Q6, and PBX1_01 (Table 3) were found. 
Discussion
Identification of the binding sites of TFs on the genome is important for understanding the mechanism of function of genes. ChIP-combined nextgeneration sequencing can identify physical interactions between proteins and DNA in living cells and provide a whole-genome view of protein-DNA interactions (Barski and Zhao, 2009; Gilchrist et al., 2009; Visel et al., 2009) . OCT4 has been considered as a major factor which could induce pluripotency in both mouse and human somatic cells. It plays a key role in the process of self-renewal and pluripotency. Recently, OCT4 was consistently detected in several cancers and was shown to be able to contribute to cancer processes including proliferation and invasion, and to the property of chemoradioresistance. The diverse functions of OCT4 in cancer suggested that we should study its target genes genome-wide.
In the present study, we used ChIP-seq to identify OCT4 binding regions in human glioblastoma cancer cells and found that OCT4 binding regions were enriched for AT with a consensus sequence TTTkswTw. The consensus sequence of OCT4 binding regions is consistent with previous in vitro studies in stem cells (Williams et al., 2004; OkumuraNakanishi et al., 2005; Tay et al., 2008) , which showed that the OCT4 protein binds DNA through AT-rich sequences with the motifs TTTGCwT (w=T or A). Marson et al. (2008) used ChIP-seq to identify binding regions of OCT4, SOX2, NANOG, and TCF3, and discovered that these four factors co-occupy 14 230 sites in the genome. They showed that about 25% of binding sites were within 8 kb of the TSSs of 3 289 annotated genes, 25% were within genes with a distance of more than 8 kb to the TSSs, and almost 50% occurred in intergenic regions far away from annotated start sites. In our study, we found that about 66.79% of OCT4 binding regions (3 632 of 5 438) mapped within 8 kb of the TSSs and about 42.72% (2 323 binding regions) mapped within 2 kb of the TSSs in glioblastoma cancer cells.
ChIP-seq technology has been applied to the identification of target genes of OCT4, SOX2, and NANOG in human embryonic stem cells by Boyer et al. (2005) . They identified 605 of the OCT4 binding promoter regions for known protein-coding genes in human embryonic stem cells. In our study, we found that 279 regions corresponding to 93 genes overlapped with our data. This suggests that the genes that are regulated by OCT4 are conserved in embryonic stem cells and brain tumor cells.
Previous studies suggested that the OCT4 protein could either activate or repress specific target genes through interaction with different partner proteins such as SOX2 and NANOG (Tay et al., 2008) . OCT4 target specificity may depend on its interacting proteins, which may include other TFs, co-activators, repressors and other proteins. These interacting proteins may interact with OCT4 to modulate OCT4's role as a TF. In the present study, we searched for the potential known TF binding motif in OCT4 binding regions. These TFs may act as OCT4 cooperators and regulate expression of many genes together with OCT4 in glioblastoma cancer.
The enriched analysis of GO terms suggested that OCT4 is involved in some important biological processes, including gene expression (GO:0010467), translation (GO:0006412), mRNA processing (GO:0006397), wound healing (GO:0042060), and apoptosis (GO:0006915).
In summary, our genome-wide analysis of protein-DNA interaction in glioblastoma cells may help to explain the role of OCT4 in glioblastoma carcinogenesis. 
